Cantargia Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Goran Forsberg

Chief Executive Officer (CEO)

kr5.4m

Compensación total

Porcentaje del salario del CEO	44.0%
Permanencia del CEO	10yrs
Participación del CEO	0.2%
Permanencia media de la dirección	2.5yrs
Promedio de permanencia en la Junta Directiva	3.7yrs

Actualizaciones recientes de la dirección

Recent updates

An Intrinsic Calculation For Cantargia AB (publ) (STO:CANTA) Suggests It's 47% Undervalued

May 31

Here's Why We're Not Too Worried About Cantargia's (STO:CANTA) Cash Burn Situation

May 02

Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?

Jan 10

We Think Cantargia (STO:CANTA) Can Easily Afford To Drive Business Growth

Sep 20

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Goran Forsberg en comparación con los beneficios de Cantargia?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-kr241m
Dec 31 2023	kr5m	kr2m	-kr280m
Sep 30 2023	n/a	n/a	-kr299m
Jun 30 2023	n/a	n/a	-kr293m
Mar 31 2023	n/a	n/a	-kr330m
Dec 31 2022	kr5m	kr2m	-kr372m
Sep 30 2022	n/a	n/a	-kr385m
Jun 30 2022	n/a	n/a	-kr419m
Mar 31 2022	n/a	n/a	-kr411m
Dec 31 2021	kr5m	kr2m	-kr367m
Sep 30 2021	n/a	n/a	-kr319m
Jun 30 2021	n/a	n/a	-kr255m
Mar 31 2021	n/a	n/a	-kr206m
Dec 31 2020	kr6m	kr2m	-kr173m
Sep 30 2020	n/a	n/a	-kr153m
Jun 30 2020	n/a	n/a	-kr139m
Mar 31 2020	n/a	n/a	-kr127m
Dec 31 2019	kr4m	kr2m	-kr111m
Sep 30 2019	n/a	n/a	-kr102m
Jun 30 2019	n/a	n/a	-kr98m
Mar 31 2019	n/a	n/a	-kr101m
Dec 31 2018	kr3m	kr1m	-kr91m
Sep 30 2018	n/a	n/a	-kr78m
Jun 30 2018	n/a	n/a	-kr68m
Mar 31 2018	n/a	n/a	-kr56m
Dec 31 2017	kr3m	kr1m	-kr60m

Compensación vs. Mercado: La compensación total de Goran($USD496.37K) está por encima de la media de empresas de tamaño similar en el mercado Swedish ($USD238.31K).

Compensación vs. Ingresos: La compensación de Goran ha aumentado mientras la empresa no es rentable.

CEO

Goran Forsberg (61 yo)

10yrs

Permanencia

kr5,404,000

Compensación

Mr. Goran Forsberg has been Independent Director at Guard Therapeutics International AB (publ) since May 2019. He has been the Chief Executive Officer at Cantargia AB (publ) since June 2014. Mr. Forsberg s...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Goran Forsberg	Chief Executive Officer	10yrs	kr5.40m	0.17% SEK 1.4m
Thoas Fioretos	Founder & Scientific Advisor	no data	kr355.00k	sin datos
Marcus Järås	Founder & Scientific Advisor	no data	sin datos	sin datos
Kjell Sjöström	Founder	no data	sin datos	sin datos
Patrik Renblad	Chief Financial Officer	less than a year	sin datos	sin datos
Liselotte Larsson	Chief Operating Officer	10.4yrs	sin datos	0.035% SEK 306.9k
David Liberg	Chief Scientific Officer	less than a year	sin datos	sin datos
Nina Valkama	Executive Assistant of Administration & Finance	2.5yrs	sin datos	sin datos
Dominique Tersago	Chief Medical Officer	1.8yrs	sin datos	sin datos
Johanna Christensen	Financial Controller	2.5yrs	sin datos	sin datos

2.5yrs

Permanencia media

61yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CANTA se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Gunnar Magnus Severus Persson	Independent Chairman of the Board	8.4yrs	kr854.00k	sin datos
Damian Marron	Independent Director	3.1yrs	kr350.00k	sin datos
Anders Martin-Lof	Independent Director	6.1yrs	kr473.00k	sin datos
Magnus Nilsson	Independent Director	3.1yrs	kr342.00k	sin datos
Flavia Borellini	Independent Director	3.7yrs	kr550.00k	sin datos

3.7yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de CANTA se considera experimentada (3.5 años de antigüedad promedio).

Cantargia Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Chief Executive Officer recently bought kr104k worth of stock

Chief Executive Officer recently bought kr103k worth of stock

Cantargia AB (publ), Annual General Meeting, May 23, 2024

Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer

Cantargia Appoints Patrik Renblad as Chief Financial Officer

Recent updates

Insufficient new directors

Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy

Forecast to breakeven in 2026

New major risk - Revenue and earnings growth

We're A Little Worried About Cantargia's (STO:CANTA) Cash Burn Rate

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition

Cantargia AB (publ) Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal

New minor risk - Share price stability

Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

Cantargia AB (publ) Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia

Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis

Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer

Price target decreased by 7.3% to kr12.67

Forecast to breakeven in 2026

New major risk - Financial position

Cantargia AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab

Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy

Chief Executive Officer recently bought kr104k worth of stock

Cantargia Reports Phase I Clinical Progress in the CAN10 Project

Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10

Chief Executive Officer recently bought kr103k worth of stock

New major risk - Revenue and earnings growth

New major risk - Financial position

Cantargia AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Cantargia AB (publ), Annual General Meeting, May 23, 2024

New minor risk - Shareholder dilution

Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer

Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR

Cantargia AB (publ) Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant

Cantargia AB (publ)Expands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases

No longer forecast to breakeven

New major risk - Financial position

Cantargia AB (publ) to Report Q1, 2024 Results on May 21, 2024

Cantargia AB (publ) Receives Regulatory Approval to Start Phase I Clinical Trial for CAN10

New minor risk - Share price stability

Is Cantargia (STO:CANTA) In A Good Position To Deliver On Growth Plans?

Cantargia Publishes ASCO 2023 Poster on Promising Nadunolimab Efficacy in Non-Small Cell Lung Cancer

Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer

Cantargia Extends Development of Nadunolimab in Pancreatic Cancer with New Controlled Phase IIb Clinical Trial Following Strong Phase IIb Efficacy Results

We Think Cantargia (STO:CANTA) Can Afford To Drive Business Growth

Cantargia Appoints Patrik Renblad as Chief Financial Officer

Chief Executive Officer recently bought kr140k worth of stock

Cantargia AB (publ) Successfully Concludes Toxicity Study with Can10 Antibody Ahead of Phase I Clinical Trial Application

Cantargia AB (Publ) Announces Nomination Committee Appointments

Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?

Price target decreased to kr22.00

Cantargia's CAN10 Demonstrates Positive Activity in Systemic Sclerosis Models in New Data Presented At ACR Convergence 2022

Cantargia AB (Publ) Presents New Data At SITC 2022 Supporting Nadunolimab's Promising Antitumor Clinical Efficacy

Cantargia Reaches Recruitment Milestone and Focuses Nadunolimab Development on Upcoming Randomized Studies

Cantargia AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Cantargia Reports First Non-Squamous NSCLC Patient Treated with Nadunolimab, Keytruda® and Chemotherapy

Cantargia Reports Preclinical Data Demonstrating Unique Treatment Effects of nadunolimab on Pancreatic Cancer Stromal Cells

Cantargia AB (Publ) Publishes Preclinical Data on Strong Anti-Tumor Efficacy of Nadunolimab in Combination with Chemotherapy

Cantargia Reports New Positive Preclinical Efficacy Data for CAN10 Supporting Development in Myocarditis

Cantargia Receives USPTO Notice of Allowance for Composition of Matter Patent on Antibody CAN10

Cantargia AB (Publ) Announces Executive Changes

An Intrinsic Calculation For Cantargia AB (publ) (STO:CANTA) Suggests It's 47% Undervalued

Cantargia Announces ASCO 2022 Presentation Strengthens Positive Phase IIa interim results for nadunolimab in NSCLC

Cantargia AB (publ) Presents Clinical Interim Results At ASCO 2022 Highlighting the Potential of Nadunolimab in Combination with Checkpoint Inhibitor

Cantargia AB (publ) Reports Positive Preclinical Effects in Atherosclerosis Demonstrating Potential of Can10 in Cardiovascular Disease

Forecast breakeven date pushed back to 2024

Here's Why We're Not Too Worried About Cantargia's (STO:CANTA) Cash Burn Situation

Price target decreased to kr42.00

Forecast breakeven date pushed back to 2024

Insider recently bought kr88k worth of stock

Cantargia Reports Positive Preclinical Efficacy Data for CAN10 Demonstrating Anti-Fibrotic and Anti-Inflammatory Effects in Systemic Sclerosis

Cantargia AB (Publ) Reports Encouraging New CAN10 Toxicology Results and Schedules Phase I Trial for 2023

Cantargia AB Reports Treatment of First Non-Squamous Non-Small Cell Lung Cancer Patient in New Arm of CANFOUR Study